ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases

Area of Science:

• Cardiovascular Medicine
• Genetics
• Pharmacology

Background:

• Optimal management of low-density lipoprotein cholesterol (LDL-C) is crucial for preventing atherosclerotic cardiovascular disease (ASCVD).
• Residual cardiovascular risk persists despite guideline-directed LDL-C levels, often due to mixed hyperlipidemia with elevated triglyceride-rich lipoproteins.
• Human genetics identifies angiopoietin-like 3 (ANGPTL3) as a key therapeutic target.

Purpose of the Study:

• To explore the role of ANGPTL3 in lipid metabolism and cardiovascular risk.
• To review the therapeutic potential of ANGPTL3 inhibition for managing hyperlipidemia and reducing ASCVD.
• To assess the safety and efficacy of emerging ANGPTL3-targeting therapies.

Main Methods:

• Genetic epidemiological studies linking ANGPTL3 loss-of-function to lipid levels and coronary artery disease risk.
• Review of pharmacological approaches including monoclonal antibodies, antisense oligonucleotides, and gene editing targeting ANGPTL3.
• Analysis of early clinical studies on the safety and efficacy of ANGPTL3 inhibitors.

Main Results:

• ANGPTL3 loss-of-function is strongly associated with lower LDL-C, triglycerides, and reduced coronary artery disease risk.
• Pharmacological inhibition of ANGPTL3 demonstrates safety and efficacy in lowering both LDL-C and triglycerides.
• Monoclonal antibodies targeting ANGPTL3 are approved for homozygous familial hypercholesteremia.

Conclusions:

• ANGPTL3 is a validated therapeutic target for lowering atherogenic lipoproteins.
• Inhibition of ANGPTL3 offers a novel strategy to address residual cardiovascular risk in hyperlipidemia.
• Further long-term studies are warranted to confirm the cardiovascular event reduction benefits of ANGPTL3 inhibition.